Biochemical Study on Activated Immune Cells Isolated from Human Hepatocellular Carcinoma

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common neoplasm in the world and the third leading cause of cancer death worldwide. It represents one of the most resistant types of malignancy, as systemic therapy with cytotoxic drugs provides only marginal benefits, especially with advanced stages. Attempts to induce an effective immune response against cancer by immunotherapeutic intervention, including activation of dendritic cells, were established. The current study was designed to investigate the possible enhancement of antigen presentation following attenuation of cancer cells ex-vivo using ribonuclease A (RNase A) as a probable vaccination to sensitize allogenic or autogenic DCs and lymphocytes isolated from Egyptian HCC patients.